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Abstract
Topoisomerase II inhibitors are effective chemotherapeutic agents in the treatment of cancer, in spite of being asso-
ciated with the development of secondary leukemia. Our purpose was to determine the effects of etoposide on differ-
ent genomic regions, aiming at discovering whether there are preferential sites which can be targeted by this drug in
peripheral lymphocytes from healthy individuals. The in vitro treatment with low doses of etoposide (0.25, 0.5, and
1 g/mL, in 1 hour-pulse or continuous-48 h treatment) induced a significant increase in chromosomal aberrations,
detected by conventional staining and FISH with specific probes for chromosomes 8 and 11, compared with un-
treated controls (p < 0.05). Additionally, the frequencies of alterations at 11q23, detected by MLL specific probes,
were significantly higher (p < 0.005) in treated cells than in controls. In contrast, an analysis of rearrangements in-
volving the IGH gene did not disclose differences between treatments. The present results demonstrated the poten-
tial of etoposide to interact with preferential chromosome sites in human lymphocytes, even at concentrations below
the mean plasma levels measured in cancer patients. This greater susceptibility to etoposide-induced cleavage may
explain the more frequent involvement of MLL in treatment-related leukemia.
Key words: etoposide, FISH, MLL translocations.
Received: July 2, 2008; Accepted: August 27, 2008.
Introduction
Etoposide is one of the most effective anticancer
drugs frequently used for the treatment of hematological
malignancies and solid tumors. However, its use has been
associated with the development of secondary leukemia.
The main target of this drug is the nuclear enzyme DNA-
topoisomerase II that catalyzes topological changes neces-
sary for normal DNA metabolism, including replication,
transcription and recombination (Austin and Marsh, 1998).
This drug, as well as other topoisomerase II inhibitors, ex-
erts its toxic effects by inhibiting the enzyme function,
thereby causing the accumulation of cleavable complexes
and introducing high levels of transient protein-associated
breaks in the genome of treated cells (Burden and Osheroff,
1998; Hande, 1998).
Therapy related leukemias, associated with topoi-
somerase II inhibitors, often present rearrangements in-
volving the MLL gene on chromosome band 11q23, or to a
lesser extent, t(8;21), t(3;21); t(8;16), t(15;17), t(9;22) or
inv(16), to then emerge as overt leukemias in a period of 2
to 3 years following therapy completion (Felix, 1998).
The MLL gene plays an important role during fetal
development and is a critical regulator of HOX genes dur-
ing hematopoiesis. This function is subverted in leukemias
through cleavage, recombination and chimeric fusion with
more than 50 gene partners (Pais et al., 2005 Meyer et al.,
2006). However, in contrast to the diversity with which
MLL translocates, the mapping of breakpoints revealed that
most translocations occur within a 8.3 kb BamH1 fragment,
known as the break-cluster region (BCR), located between
exons 8 and 14 (Echlin-Bell et al., 2003). According to
Strout et al., (1998), the BCR region presents 8 Alu repeats,
various topoisomerase II consensus sites, 7/8 X-like
octamers and V(D)J cryptic recognition signals, which
might explain the high susceptibility of this gene to damag-
ing agents. Nonetheless, other and subsequent studies have
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shown that DNA structure properties, such as scaffold asso-
ciated regions and DNAse I hypersensitive sites, can act as
recombination hot spots (Broeker et al., 1996; Strissel et
al., 1998; Hensel et al., 2001; Reichel et al., 2001; Strick et
al., 2006).
Furthermore, the biological evidence that leukemias
in newborns originate in utero, has led to the hypothesis
that maternal exposure to topoisomerase II inhibitors dur-
ing pregnancy could be associated with an increased risk of
leukemia (Ross, 2000). It is well known that synthetic and
natural flavonoids interact with topoisomerase II and form
the cleavable complex, in spite of being anticarcinogenic in
certain cases (Greaves, 1997). According to Wiemels et al.
(1999), the exposure of mothers and fetuses to substances
that interact with the topoisomerase II inhibitors present in
diets, medicines and the environment can in order of mag-
nitude, be lower in terms of dose, when compared to the
drugs used in chemotherapy. Nevertheless, in some cases
they can be as biologically active as the topoisomerase II
inhibitors used in cancer treatment.
Therefore, by considering the more frequent involve-
ment of MLL in treatment-related leukemogenesis, we
aimed at studying whether low concentrations of etoposide
would also preferentially promote 11q23 translocations
over rearrangements within other chromosomal locations.
Material and Methods
Blood culture and metaphase preparation
Whole blood from three healthy donors (21 years old)
were collected in a vacutainer containing the anticoagulant
heparin, and cultured in a RPMI-1640 medium supple-
mented with 15% fetal bovine serum, 1% penicillin-
streptomycin, 1% l-glutamine (Gibco, Grand Island, NY),
and 1% phytohemagglutinin-P (Gibco). Cell cultures were
incubated at 37 °C in a 5% CO2 moist atmosphere and har-
vested at 72 h after culture initiation. Twenty four hours af-
ter mitogenic stimulation, Etoposide (Nex-Vep, Bristol
Myers Squibb) was added and cells were incubated for 48 h
at 37 °C in final concentrations of 0.25, 0.5 and 1 g/mL.
One set of cultures was treated for one hour-pulse, being
subsequently washed twice in a RPMI 1640 medium, and
subcultured in a supplemented medium until harvesting
(47 h recovery period). Colcemid (0.1 g/mL) was added
90 min prior to harvesting time. After hypotonic treatment
(0.075 M KCl) for 30 min at 37 °C, cells were fixed three
times with methanol: glacial acetic acid (3:1). The fixed
cells were then dropped onto glass slides, allowed to air dry
and stored at -20 °C, until being used in the FISH technique.
Fluorescence in situ hybridization
FISH was performed using the commercially avail-
able probes LSI MLL Break Apart Rearrangement, accord-
ing to manufacturer’s protocol (Vysis, Downers Grove.
IL). The Spectrum-Green labeled probe covers a 350 kb
centromeric portion of the MLL gene breakpoint region,
while the Spectrum-Orange-labeled probe covers a 190 kb
region telomeric to the BCR. In addition, LSI IGH Dual
Color Break Apart Rearrangement probes (Vysis) were
used. These probes hybridize with 14q32 and present the
same characteristics as the probes for 11q23. In both cases,
the pattern of expected signals for a normal nucleus is two
green (yellow) orange signals. In cell harboring trans-
location, the green and orange signals appear separated
without the yellow intersection. This strategy allows for the
detection of translocations irrespective of the partner in-
volved.
Chromosomal aberrations were also analyzed by us-
ing the whole chromosome painting Spectrum-Orange
WCP-8 and Spectrum-Green WCP-11 probes (Vysis).Im-
ages were captured by using the Axiovision System (Zeiss,
Germany).
Detection of apoptotic cells
Apoptotic cells were recognized by nuclear conden-
sation and fragmentation. Treated cells were centrifuged
and incubated for 5 min at 37 °C with bisbenzimide
(Hoechst 33342), propidium iodide and fluorescein
diacetate (Sigma Chemical Co., St. Louis, U S A). Then,
samples were mounted, coverslipped and analyzed by fluo-
rescence microscopy with a triple filter. Cells were scored
and categorized according to differential staining: (1) nor-
mal: blue nucleus and green cytoplasm, (2) apoptotic: frag-
mented blue nucleus and green cytoplasm and (3) necrotic:
spherical red nucleus. Five hundred nuclei were analyzed
per treatment.
Statistical analysis
Statistical analyses were performed by using
SigmaStat (Jandel Scientific, Co) software. All tests were
carried out for  = 0.05.
Results
The clastogenic effects of etoposide on different
genomic regions were analyzed in lymphocyte cultures
from 3 healthy probands. Cultures were treated with three
drug concentrations, 0.25, 0.5 and 1 g/mL. Etoposide-
treated cells presented a reduction in mitotic indexes (cal-
culated for 1000 cells), albeit there were no significant dif-
ferences among treatments (p > 0.05). Etoposide induced a
statistically significant increase in frequencies of chromo-
some aberration relative to negative controls (p < 0.0005,
One Way Repeated Measures ANOVA). On comparing the
different treatments and controls, the Bonferroni method
showed significant differences for continuous exposure to
etoposide (p < 0.05) (Table 1). Cytogenetic analysis by
FISH with whole chromosome probes indicated increased
frequencies of altered cells and aberrations located at chro-
mosome 11, when treated cultures and controls were com-
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pared (p < 0.05, Friedman Repeated Measures ANOVA on
Ranks), in both cases (Table 2). Mean numbers of 800
metaphases were analyzed. Alterations in chromosome 8
also showed increased frequencies (p < 0.05). For both
chromosomes, the comparison of different treatments
against controls performed by the Bonferroni method
showed significant differences for continuous exposure to
etoposide (p < 0.05). The individual comparison of mean
aberration frequencies per treatment calculated for chromo-
somes 8 and 11 showed statistically higher frequencies for
chromosome 11 than for chromosome 8, in some drug con-
centrations (Figure 1).
The specific induction of translocations at 11q23 was
also analyzed by using the MLL gene probe (Vysis). MLL
rearrangements were scored in nuclei presenting a hybrid-
ization pattern with clearly distinct separation of signals.
Statistical analysis showed significant differences
(p < 0.0005, One Way ANOVA) between treated and un-
treated cultures. In contrast, the analysis of rearrangements
involving the IGH gene (14q32) did not disclose significant
differences between treatments (p > 0.05, One-Way Re-
peated Measures ANOVA) (Figure 2). Extra signals were
also detected by both specific probes, but their frequencies
were not significantly increased (p > 0.05) in treated cul-
tures. Hybridization patterns and examples of chromosome
aberrations are presented in Figure 3.
It has been suggested that MLL aberrations could re-
sult from chromatin fragmentation at initial stages of
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Table 1 - Mitotic indexes, chromosome aberration distribution (CAs), total CAs and altered metaphases in cultures treated with etoposide. Independent
experiments were performed with blood samples from three individuals.
Treatment Mitotic index (mean  SD) Total CAs#/100 cells (mean  SD) Altered Metaphases/100 cells (mean  SD)
Control 5.14  2.30 1.58  0.57 1.58  0.57
0.25 g/mL (1 h) 5.79  2.28 7.3  0.57 6.31  0.57
0.5 g/mL (1 h) 5.12  1.04 8.14  2.08 6.83  1.73
1 g/mL (1 h) 4.78  2.34 9.22  3.78 7.36  2.51
0.25 g/mL (48 h) 2.71  1.04 81.97  13.20* 35.72  11.53*
0.5 g/mL (48 h) 2.92  1.36 93.77  58.73* 45.88  22.94*
1 g/mL (48 h) 1.89  0.17 168.76  44.19* 74.01  12.42*
#Chromosome aberrations included chromatidic and chromosome gaps. chromatid and chromosome breaks; fragments. double minutes and other aberra-
tions such as rings. dicentrics. triradial. tetraradial. and complex aberrations.
*Statistically different. p < 0.05.
Modality of treatment is indicated in brackets: 1 h pulse and 48 h continuous treatment.
Table 2 - Altered metaphases and chromosomal aberrations (CAs) de-
tected with specific probes for chromosomes 8 and 11 in peripheral blood
lymphocytes treated with etoposide. 1000 cells were analyzed per treat-
ment/experiment.
Treatment Altered Metaphases/100
cells (meanSD)
Total CAs#/100 cells
(meanSD)
Chromosome 11
Control 2.00  2.00 0.186  0.19
0.25 g/mL (1 h) 3.03  2.88 0.46  0.18
0.5 g/mL (1 h) 3.10  7.81 0.34  0.82
1 g/mL (1 h) 4.04  4.93 0.46  0.46
0.25 g/mL (48 h) 21.10  9.45* 2.11  0.94*
0.5 g/mL (48 h) 17.01  9.60* 3.89  0.67*
1 g/mL (48 h) 48.70  19.13* 9.85  4.21*
Chromosome 8
Control 0.33  0.57 0.03  0.00
0.25 g/mL (1 h) 0.66  0.57 0.08  0.00
0.5 g/mL (1 h) 2.15  2.08 0.22  0.24
1 g/mL (1 h) 3.33  2.88 0.22  0.30
0.25 g/mL (48 h) 6.46  2.08* 0.70  0.16*
0.5 g/mL (48 h) 15.28  1.52* 1.76  0.55*
1 g/mL (48 h) 12.29  13.45* 3.28  1.43*
#Chromosome aberrations included chromatidic and chromosome gaps.
chromatid and chromosome breaks; fragments. double minutes and other
aberrations such as rings. dicentrics. triradial. tetraradial. and complex ab-
errations.
*Statistically different. p < 0.05.
Modality of treatment is indicated in brackets: 1 h pulse and 48 h continu-
ous treatment.
Figure 1 - Mean aberration frequencies on chromosomes 8 and 11 (de-
tected by chromosome painting), observed in lymphocyte cultures treated
with different etoposide concentrations and negative controls. P: one-
hour-pulse treatment.*Statistically different p < 0.05.
apoptosis. However, treated lymphocytes did not show
etoposide-induced apoptosis (p > 0.05). Similarly, frequen-
cies of necrotic cells did not significantly differ (p > 0.05)
from controls (Figure 4).
Discussion
In the present study, we observed a statistically sig-
nificant increase in the frequencies of chromosome aberra-
tion in peripheral lymphocyte cultures treated with low
etoposide concentrations. On comparing with controls, this
increase proved to be higher in the continuous 48 h treat-
ment. Treated cultures also showed a reduction in mitotic
indexes, even though the differences between treatments
were not significant. Several studies have demonstrated
that cells are more sensitive to etoposide when treated dur-
ing the S-phase of the cell cycle, although formation of the
cleavable complex has been reported to occur at all phases
(Berger et al., 1991). It has been suggested that at low con-
centrations, the cleavable complex could initiate a series of
events that would culminate in the elimination of cells
through necrosis or apoptosis (Froelich-Ammon and
Osheroff, 1995). In the present study, the morphological
analysis of cells by differential fluorescent staining did not
show significant induction of apoptotic and necrotic cells
by different etoposide concentrations.
A direct correspondence between topoisomerase II
consensus sequences and the breakpoints described in ther-
apy-related leukemias has been reported (Felix, 1998). Fur-
thermore, rearrangements at 11q23 are highly reproducible
in culture under conditions of treatment with topoiso-
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Figure 2 - MLL (A) and IGH (B) mean translocation and extra signal fre-
quencies observed in peripheral blood lymphocytes cultures treated with
different etoposide concentrations. P: one-hour-pulse treatment. *statisti-
cally different. p < 0.05.
Figure 4 - Mean aberration frequencies of apoptotic (white bars) and ne-
crotic (grey bars) cells observed in negative controls and in lymphocyte
cultures treated with different etoposide concentrations: A) One-hour-
pulse treatment and B) continous 48 h treatment.
Figure 3 - FISH analysis of peripheral lymphocytes treated with etopo-
side. a) and b) Normal methaphase with two MLL copies at 11q23 and
translocated nucleus presenting the separation of signals, respectively.
c) Normal metaphase with two IGH gene copies at 14q32. d) Translocated
nucleus presenting the separation of signals. e) Normal metaphase show-
ing chromosome pair 8 (WCP 8 Spectrum-Green) and chromosome pair
11 (WCP 11 Spectrum-orange). f) Partial metaphase showing a triradial
chromosome involving both chromosomes. g) Partial metaphase showing
a chromatid break. Figures of altered cells correspond to 1 L/mL etopo-
side treatment.
merase II inhibitors (Aplan et al., 1996). There is also evi-
dence that etoposide-metabolites, cathecol and quinone,
also induce breaks at MLL BCR, as observed for the drug it-
self (Lovett et al., 2001). The present results demonstrate
the clastogenic activity of etoposide, even at low concentra-
tions over short periods, placed in evidence by the induc-
tion of aberrations at chromosome 11 and MLL gene, as
detected by FISH with specific probes. Aplan et al. (1996)
showed that double-strand breaks can be induced in vitro in
myeloid lineages with concentrations as low as 3 mol
(1.7 g/mL), and that such breaks increase with higher
doses, with a plateau at concentrations between
30-100 mol (17-58 g/mL). These authors also demon-
strated that site-specific cleavage did not require continu-
ous treatments, since cells treated for one hour and
recovered after 24 h presented specific cleavage at 11q23.
Our results showed differences between treated and
untreated cells even at the lowest concentration (etoposide
0.25 g/mL), ~0.4 mol, for one-hour pulse. However, the
clastogenic effect was more pronounced under conditions
of continuous treatments for 48 h, which is the maximum
period of drug stability in cultures (Mader et al., 1991).
Even though Aplan et al. (1996) showed that the induction
of aberrations did not require continuous drug exposure,
other authors demonstrated that the effects of topoiso-
merase II inhibitors disappear after drug removal (Binaschi
et al., 1990), suggesting that at low concentrations the pos-
sibilities of DNA repair seem to be higher.
Regarding aberrations at the MLL gene, Moneypenny
et al. (2006) demonstrated the induction of breaks (assessed
by the comet assay) in fetal hematopoietic cells exposed to
low concentrations of etoposide (0.3 g/mL). Furthermore,
increased frequencies of MLL rearrangements were also de-
tected by FISH after 24 h, 72 h and 7 days following treat-
ment with etoposide 0.3 and 0.6 g/mL.
The recurrent association of 11q23 translocations
with therapy-related leukemias has led to the suggestion
that this region might be preferentially damaged by topoi-
somerase II inhibitors, and consequently, chromosome 11
might present more aberrations compared with other chro-
mosomes. With this in view, we proposed to analyze in-
duced-damage at chromosome 8 (involved to a lesser
extent as it is in leukemia-associated translocations) and at
the IGH gene (14q32), also involved in lymphoid malig-
nancies.
The analysis of chromosome 8 showed a significant
increase of chromosomal aberrations in treated cultures rel-
ative to controls, in continuous treatment with etoposide
(0.5 and 1 g/mL), but a comparison of mean aberration
frequencies calculated for chromosomes 8 and 11 showed
significantly higher frequencies for 11 compared to 8. In
addition, rearrangements involving the IGH gene (14q32)
did not significantly (p > 0.05) increase after etoposide
treatment, indicating that this gene is not affected to the
same extent as the MLL gene by induced-chromosome
breaks under the same conditions.
Similarly, the non-random induction of aberrations
by etoposide was previously reported by Maraschin et al.
(1990), demonstrating that chromosomes 1, 11 and 17 were
more involved in aberrations than chromosomes 4, 5 and X,
which were rarely affected. Regarding other chromosomes,
Mosesso et al., (1998) showed that the frequencies of aber-
rations at chromosomes 2, 4 and 8 were 20%-30% higher
than those observed for chromosomes 1, 3 and X.
Differences in susceptibility to induced-breaks might
be related to certain characteristics of chromosome struc-
ture, since R-band rich chromosomes, such as chromosome
11, are more sensitive than G-band rich ones (Maraschin et
al., 1990). In CD34+ cells treated with etoposide, Libura et
al. (2005) showed that aberrations at chromosome 11 occur
at frequencies twice as high as at chromosome 4, suggest-
ing that even though t(4;11) is the most frequent trans-
location in some leukemias, there is still a difference
concerning susceptibility to etoposide induced-damage.
Also, Escobar et al. (2007) showed by comet-FISH assays
that etoposide produced more DNA damage at 11q23 in re-
lation to the long arm of chromosomes 5, more specifically
5q31, which is often deleted secondary leukemias associ-
ated by previous treatment with alkylating agents.
Previous studies on drug clastogenicity performed at
the gene level were unable to detect specific damage at sev-
eral loci, including SCL, ENL, AF6, TCR, TCR and
TCR, in etoposide-treated cells (Aplan et al., 1996). Like-
wise, Ng et al. (2006) reported a higher susceptibility of the
MLL gene to treatments with etoposide 10-100 mol com-
pared to the leukemia-associated RUNX1 and AF9 genes.
It has been reported that the origin of gene fusions in
lymphoid malignancies, such as t(14;18) IGH/BCL2,
t(11;14) IGH/CCD1, t(11;14) LMO2/TCR and t(7;9)
TCR/TAL2, among others, might involve the V(D)J recom-
bination process (responsible for the rearrangements at
T-cell receptor and immunoglobulin genes), apparently
through the recognition of heptamer-nonamer cryptic se-
quences (Vega and Medeiros, 2003).
Increased illegitimate recombination frequencies at
TCR genes have been identified in agricultural workers ex-
posed to pesticides (Lipkowitz et al., 1992) and in patients
under chemotherapy (Abdallah et al., 1995). Chen et al.
(1996) demonstrated that etoposide induces site-specific
rearrangements consistent with V(D)J-recombinase, by
studying deletions at the HPRT gene level. The loss of
exons 2 and 3 appeared to have increased in non-lymphoid
cells in a concentration-dependent manner under continu-
ous etoposide-treatment.
In our study, the analysis of the IGH gene (14q32)
demonstrated only a slight increase in the frequency of ab-
errations, through different treatments for one hour-pulse.
Illegitimate V(D)J recombination has also been associated
with the origin of MLL aberrations, probably due to the
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presence of consensus signal sequences at BCR. Gu et al.
(1992) reported cryptic heptamer-nonamer sequences
when analyzing breakpoints at MLL and AF4, involved in
t(4;11), suggesting that the V(D)J-recombinase complex
could be directly associated with the emergence of trans-
location. The involvement of this process has also been
suggested by Whitmann et al., (2001), who detected illegit-
imate recognition sequences at the breakpoint junctions be-
tween MLL intron 6 and AF9 intron 8 in patients with
leukemia harboring t(9;11). In parallel, several studies have
demonstrated the induction of MLL aberrations after expo-
sure of cells to different apoptotic stimuli (Stanulla et al.,
1997; Sim & Liu , 2002; Betti et al., 2003).
However, there is increasing evidence showing that
certain properties related to DNA structure, such as scaf-
fold associated regions and DNAse I hypersensitive sites,
indeed act as recombination hot spots (Broeker et al.,
1996; Strissel et al., 1998; Hensel et al., 2001; Reichel et
al., 2001; Strick et al., 2006). Interestingly, Scharf et al.,
(2007) demonstrated that the etoposide cleavage site at the
MLL gene resides within a RNA polymerase II binding
site.
In childhood leukemia patients, the mean plasma
concentration of topoisomerase II inhibitors is 1.7 mol
(1 g/mL) in chronic treatments (Edick et al., 2003),
reaching 25 mol after 6 h from administration in some
treatment schedules. Some controversy exists in the litera-
ture regarding dosage and duration of treatment in the de-
velopment of therapy-related leukemias. According to
Megonigal et al. (2000), there is a dose-response relation-
ship in patients treated with alkylating agents but this
would not be the case for patients treated with epipo-
dophyllotoxins. On the contrary, other authors postulate
the existence of a direct leukemogenic effect after etopo-
side treatment, dependent on the time and dose adminis-
tered (Dann and Rowe, 2001). There are reports of t-AML
development after exposure to few doses of topoiso-
merase II inhibitors (Blanco et al., 2001).
Although the factors influencing the predisposition of
the MLL gene to induced damage by topoisomerase II in-
hibitors are still unknown, the presence of topoisomerase II
consensus sites, scaffold-associated regions and other se-
quences (such as Alu repeats, cryptic V(D)J signal and 7/8
X-like sequences, among others), suggest that this gene
might be more vulnerable to breakage by enzymes, toxic
chemicals and metabolites.
Thus, the increase of MLL aberrations induced after
treatment with low doses of etoposide, as shown in the
present study, provides relevant information regarding
the potential effects of etoposide in in vivo exposure,
demonstrating the evident predisposition of this gene to
drug-induced chromosome damage, even at concentra-
tions below the limits observed for patients under che-
motherapy.
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